Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 2067526
PUBLISHER: Grand View Research | PRODUCT CODE: 2067526
U.S. Medical Foods Market Size, Share & Trends Analysis Report By Route Of Administration, By Product, By Application, By Sales Channel, By Module, And Segment Forecasts, 2026 - 2033
PUBLISHED:
PAGES: 90 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
U.S. Medical Foods Market Summary
The U.S. medical foods market size was estimated at USD 6.9 billion in 2025 and is projected to reach USD 10.7 billion by 2033, growing at a CAGR of 5.5% 2026 to 2033. This growth is driven by the rising geriatric population, growing prevalence of chronic diseases, and increasing adoption of disease-specific nutritional formulas.
The growing prevalence of chronic diseases further accelerates demand for disease-specific nutritional interventions. According to the data published by the Centers for Disease Control and Prevention in April 2025, approximately 194 million U.S. adults, which is 76.4%, reported at least one chronic condition, while over 51% had multiple chronic conditions. Among older adults, the burden is even higher, with nearly 93% of individuals aged 65+ having at least one chronic disease in 2023.
Neurological conditions such as Alzheimer's are particularly significant, with about 7.2 million Americans currently living with the disease, and projections indicating continued growth. This rising disease burden creates sustained demand for medical foods as adjunct therapy in clinical treatment pathways.
The rising incidence of chronic and rare diseases, along with advances in targeted therapies, is driving demand for disease-specific medical foods. These products are increasingly used in the management of conditions such as cancer, gastrointestinal disorders, and metabolic diseases, where tailored nutrition is essential to support treatment outcomes and avoid drug-nutrient interactions. For instance, gastrointestinal patients require easily digestible, tolerance-focused formulas, while oncology patients benefit from high-protein, energy-dense solutions to manage treatment-related complications. Leading companies such as
- Abbott Osmolite 1.2 / 1.5 Cal: A fiber-free enteral formula designed for patients with gastrointestinal intolerance, supporting nutrient absorption and tolerance in sensitive patients.
- Danone Milupa Product Range: Foods for Special Medical Purposes (FSMPs) intended for the dietary management of inherited metabolic disorders, supporting growth and nutrient requirements under medical supervision.
- Nestle BOOST SOOTHE: A clear, high-calorie oral nutritional supplement designed for patients experiencing oral discomfort, taste changes, or mucositis, particularly during cancer treatment. It provides 300 kcal and 10 g of protein per serving, in a soothing, easy-to-drink format, to help maintain weight and nutrition.
U.S. Medical Foods Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. medical foods market report based on route of administration, product, application, module, sales channel, and region:
- Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
- Oral
- Enteral
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Powder
- Pills
- Liquid
- Other
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Chronic Kidney Disease
- Minimal Hepatic Encephalopathy
- Chemotherapy-Induced Diarrhea
- Pathogen-Related Infections
- Diabetic Neuropathy
- ADHD
- Depression
- Alzheimer's Disease
- Nutritional Deficiency
- Orphan Diseases
- Tyrosinemia
- Eosinophilic Esophagitis
- FPIES
- Phenylketonuria
- MSUD
- Homocystinuria
- Others
- Wound Healing
- Chronic Diarrhea
- Constipation Relief
- Protein Booster
- Dysphagia
- Pain Management
- Parkinson's Disease
- Epilepsy
- Other cancer-related treatments
- Severe Protein Allergy
- Cancer
- Cachexia
- Other
- Module Outlook (Revenue, USD Million, 2021 - 2033)
- Amino Acid Module
- Protein Module
- Vitamin & Mineral Modules
- Fatty Acid-based Modules
- Carbohydrate Modules
- Fiber Modules
- Ketogenic Modules
- Peptide-based Modules
- Hypoallergenic Modules
- Others (Electrolyte Module, etc.)
- Sales Channel Outlook (Revenue, USD Million, 2021 - 2033)
- DTC Sales Channel
- Online Sales
- Retail Sales
- Institutional Sales
- Hospitals
- Others (Long-term Care Facilities, etc.)
Product Code: GVR-4-68040-297-0
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Market Definitions
- 1.3. Information Procurement
- 1.3.1. Purchased Database
- 1.3.2. GVR's Internal Database
- 1.3.3. Secondary Sources & Third-Party Perspectives
- 1.3.4. Primary Research
- 1.3.5. Details of Primary Research
- 1.4. Information Analysis
- 1.4.1. Data Analysis Models
- 1.5. Market Formulation & Data Visualization
- 1.5.1. Commodity Flow Analysis
- 1.5.1.1. Approach 1: Commodity flow approach
- 1.5.1.2. Approach 2: Country-wise market estimation using a bottom-up approach
- 1.5.1. Commodity Flow Analysis
- 1.6. Data Validation & Publishing
- 1.7. U.S. Market: CAGR Calculation
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segmental Snapshot
- 2.3. Competitive Insights Snapshot
Chapter 3. Market Variables, Trends, and Scope
- 3.1. Market Lineage
- 3.1.1. Ancillary Market Analysis
- 3.2. U.S. Medical Foods Market - Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Growing prevalence of chronic diseases
- 3.2.1.2. Rising geriatric population
- 3.2.1.3. Shifting trend toward consumption of disease-specific formulas
- 3.2.1.4. Growing demand for neonatal and preterm enteral
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Limited reimbursement and insurance coverage
- 3.2.2.2. Regulatory ambiguity and lack of clear classification
- 3.2.3. Market Opportunity Analysis
- 3.2.4. Market Challenge Analysis
- 3.2.1. Market Driver Analysis
- 3.3. Pricing Analysis
- 3.4. Industry Analysis
- 3.4.1. User Perspective Analysis
- 3.4.2. Key End Users
- 3.5. Technology Outlook
- 3.5.1. Technology Timeline
- 3.6. Business Environmental Tools Analysis: U.S. Medical Foods Market
- 3.6.1. Porter's Five Forces Analysis
- 3.6.2. PESTLE Analysis
Chapter 4. U.S. Medical Foods Market: Route of Administration Estimates & Trend Analysis
- 4.1. U.S. Medical Foods Market, By Route of Administration: Key Takeaways
- 4.2. U.S. Medical Foods Market: Route of Administration Movement & Market Share Analysis, 2025 & 2033
- 4.3. Oral
- 4.3.1. U.S. Oral Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4. Enteral
- 4.4.1. U.S. Enteral Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. U.S. Medical Foods Market: Product Estimates & Trend Analysis
- 5.1. U.S. Medical Foods Market, By Product: Key Takeaways
- 5.2. U.S. Medical Foods Market: Product Movement & Market Share Analysis, 2025 & 2033
- 5.3. Pills
- 5.3.1. U.S. Pills Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4. Powder
- 5.4.1. U.S. Powder Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Liquid
- 5.5.1. U.S. Liquid Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6. Others
- 5.6.1. U.S. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. U.S. Medical Foods Market: Application Estimates & Trend Analysis
- 6.1. U.S. Medical Foods Market, By Application: Key Takeaways
- 6.2. U.S. Medical Foods Market: Application Movement & Market Share Analysis, 2025 & 2033
- 6.3. Chronic Kidney Disease
- 6.3.1. U.S. Chronic Kidney Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4. Minimal Hepatic Encephalopathy
- 6.4.1. U.S. Minimal Hepatic Encephalopathy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Chemotherapy-Induced Diarrhea
- 6.5.1. U.S. Chemotherapy-Induced Diarrhea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. Pathogen-Related Infections
- 6.6.1. U.S. Pathogen-Related Infections Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.7. Diabetic Neuropathy
- 6.7.1. U.S. Diabetic Neuropathy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.8. ADHD
- 6.8.1. U.S. ADHD Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.9. Depression
- 6.9.1. U.S. Depression Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.10. Alzheimer's Disease
- 6.10.1. U.S. Alzheimer's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.11. Nutritional Deficiency
- 6.11.1. U.S. Nutritional Deficiency Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.12. Orphan Diseases
- 6.12.1. U.S. Orphan Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.12.2. Tyrosinemia
- 6.12.2.1. U.S. Tyrosinemia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.12.3. Eosinophilic Esophagitis
- 6.12.3.1. U.S. Eosinophilic Esophagitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.12.4. FPIES
- 6.12.4.1. U.S. FPIES Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.12.5. Phenylketonuria
- 6.12.5.1. U.S. Phenylketonuria Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.12.6. MSUD
- 6.12.6.1. U.S. MSUD Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.12.7. Homocystinuria
- 6.12.7.1. U.S. Homocystinuria Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.12.8. Others
- 6.12.8.1. U.S. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.13. Wound Healing
- 6.13.1. U.S. Wound Healing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.14. Chronic Diarrhea
- 6.14.1. U.S. Chronic Diarrhea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.15. Constipation Relief
- 6.15.1. U.S. Constipation Relief Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.16. Protein Booster
- 6.16.1. U.S. Protein Booster Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.17. Dysphagia
- 6.17.1. U.S. Dysphagia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.18. Pain Management
- 6.18.1. U.S. Pain Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.19. Parkinson's Disease
- 6.19.1. U.S. Parkinson's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.20. Epilepsy
- 6.20.1. U.S. Epilepsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.21. Other cancer-related treatments
- 6.21.1. U.S. Other Cancer related treatments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.22. Severe Protein Allergy
- 6.22.1. U.S. Severe Protein Allergy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.23. Cancer
- 6.23.1. U.S. Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.24. Cachexia
- 6.24.1. U.S. Cachexia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.25. Other
- 6.25.1. U.S. Other Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. U.S. Medical Foods Market: Module Estimates & Trend Analysis
- 7.1. U.S. Medical Foods Market, By Module: Key Takeaways
- 7.2. U.S. Medical Foods Market: Module Movement & Market Share Analysis, 2025 & 2033
- 7.3. Amino Acid Module
- 7.3.1. U.S. Amino Acid Module Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4. Protein Module
- 7.4.1. U.S. Protein Module Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Vitamin & Mineral Modules
- 7.5.1. U.S. Vitamin & Mineral Modules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Fatty Acid-based Modules
- 7.6.1. U.S. Fatty Acid-based Modules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Carbohydrate Modules
- 7.7.1. U.S. Carbohydrate Modules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8. Fiber Modules
- 7.8.1. U.S. Fiber Modules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.9. Ketogenic Modules
- 7.9.1. U.S. Ketogenic Modules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.10. Peptide-based Modules
- 7.10.1. U.S. Peptide-based Modules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.11. Hypoallergenic Modules
- 7.11.1. U.S. Hypoallergenic Modules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.12. Others (Electrolyte Module, etc.)
- 7.12.1. U.S. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. U.S. Medical Foods Market: Sales Channel Estimates & Trend Analysis
- 8.1. U.S. Medical Foods Market, By Sales Channel: Key Takeaways
- 8.2. U.S. Medical Foods Market: Sales Channel Movement & Market Share Analysis, 2025 & 2033
- 8.3. DTC Sales Channel
- 8.3.1. Online Sales
- 8.3.1.1. U.S. Online Sales Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.2. Retail Sales
- 8.3.2.1. U.S. Retail Sales Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.1. Online Sales
- 8.4. Institutional Sales
- 8.4.1. U.S. Institutional Sales Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.2. Hospitals
- 8.4.2.1. U.S. Hospitals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.3. Others (Long-term Care Facilities, etc.)
- 8.4.3.1. U.S. Others (Long-term Care Facilities, etc.) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Company Market Share Analysis, 2025 (%)
- 9.2. Company Categorization
- 9.3. Company Profiles/Listing
- 9.3.1. Danone
- 9.3.1.1. Overview
- 9.3.1.2. Financial Performance
- 9.3.1.3. Product Benchmarking
- 9.3.1.4. Strategic Initiatives
- 9.3.2. Nestle
- 9.3.2.1. Overview
- 9.3.2.2. Financial Performance
- 9.3.2.3. Product Benchmarking
- 9.3.2.4. Strategic Initiatives
- 9.3.3. Abbott
- 9.3.3.1. Overview
- 9.3.3.2. Financial Performance
- 9.3.3.3. Product Benchmarking
- 9.3.3.4. Strategic Initiatives
- 9.3.4. Targeted Medical Pharma, Inc.
- 9.3.4.1. Overview
- 9.3.4.2. Financial Performance
- 9.3.4.3. Product Benchmarking
- 9.3.4.4. Strategic Initiatives
- 9.3.5. Fresenius Kabi AG
- 9.3.5.1. Overview
- 9.3.5.2. Financial Performance
- 9.3.5.3. Product Benchmarking
- 9.3.5.4. Strategic Initiatives
- 9.3.6. Primus Pharmaceuticals, Inc.
- 9.3.6.1. Overview
- 9.3.6.2. Financial Performance
- 9.3.6.3. Product Benchmarking
- 9.3.6.4. Strategic Initiatives
- 9.3.7. Mead Johnson & Company, LLC (Acquired by Reckitt Benckiser Group PLC)
- 9.3.7.1. Overview
- 9.3.7.2. Financial Performance
- 9.3.7.3. Product Benchmarking
- 9.3.7.4. Strategic Initiatives
- 9.3.8. Alfasigma USA, Inc.
- 9.3.8.1. Overview
- 9.3.8.2. Financial Performance
- 9.3.8.3. Product Benchmarking
- 9.3.8.4. Strategic Initiatives
- 9.3.1. Danone
Product Code: GVR-4-68040-297-0
List of Tables
- Table 1 List of secondary sources
- Table 2 List of abbreviations
- Table 3 U.S. medical foods market, by route of administration, 2021 - 2033 (USD Million)
- Table 4 U.S. medical foods market, by product type, 2021 - 2033 (USD Million)
- Table 5 U.S. medical foods market, by application, 2021 - 2033 (USD Million)
- Table 6 U.S. medical foods market, by module, 2021 - 2033 (USD Million)
- Table 7 U.S. medical foods market, by sales channel, 2021 - 2033 (USD Million)
List of Figures
- Fig. 1 Market research process
- Fig. 2 Data triangulation techniques
- Fig. 3 Primary research pattern
- Fig. 4 Market research approaches
- Fig. 5 Value-chain-based sizing & forecasting
- Fig. 6 QFD modeling for market share assessment
- Fig. 7 Market formulation & validation
- Fig. 8 Market snapshot, 2025 (USD Million)
- Fig. 9 Market segmentation insights
- Fig. 10 Competitive landscape
- Fig. 11 Market driver impact
- Fig. 12 Market restraint impact
- Fig. 13 Porter's analysis
- Fig. 14 PESTLE analysis
- Fig. 15 U.S. Medical foods market: Route of administration type outlook and key takeaways
- Fig. 16 U.S. Medical foods market: Route of administration movement analysis
- Fig. 17 U.S. oral market, 2021 - 2033 (USD Million)
- Fig. 18 U.S. enteral market, 2021 - 2033 (USD Million)
- Fig. 19 U.S. Medical foods market: Product outlook and key takeaways
- Fig. 20 U.S. Medical foods market: Product movement analysis
- Fig. 21 U.S. pills market, 2021 - 2033 (USD Million)
- Fig. 22 U.S. powder market, 2021 - 2033 (USD Million)
- Fig. 23 U.S. liquid market, 2021 - 2033 (USD Million)
- Fig. 24 U.S. others market, 2021 - 2033 (USD Million)
- Fig. 25 U.S. Medical foods market: Application outlook and key takeaways
- Fig. 26 U.S. Medical foods market: Application movement analysis
- Fig. 27 U.S. chronic kidney disease market, 2021 - 2033 (USD Million)
- Fig. 28 U.S. minimal hepatic encephalopathy market, 2021 - 2033 (USD Million)
- Fig. 29 U.S. chemotherapy-induced diarrhea market, 2021 - 2033 (USD Million)
- Fig. 30 U.S. pathogen-related infections market, 2021 - 2033 (USD Million)
- Fig. 31 U.S. diabetic neuropathy market, 2021 - 2033 (USD Million)
- Fig. 32 U.S. ADHD market, 2021 - 2033 (USD Million)
- Fig. 33 U.S. depression market, 2021 - 2033 (USD Million)
- Fig. 34 U.S. Alzheimer's disease market, 2021 - 2033 (USD Million)
- Fig. 35 U.S. nutritional deficiency market, 2021 - 2033 (USD Million)
- Fig. 36 U.S. orphan diseases market, 2021 - 2033 (USD Million)
- Fig. 37 U.S. wound healing market, 2021 - 2033 (USD Million)
- Fig. 38 U.S. chronic diarrhea market, 2021 - 2033 (USD Million)
- Fig. 39 U.S. protein booster market, 2021 - 2033 (USD Million)
- Fig. 40 U.S. dysphagia market, 2021 - 2033 (USD Million)
- Fig. 41 U.S. pain management market, 2021 - 2033 (USD Million)
- Fig. 42 U.S. Parkinson's disease market, 2021 - 2033 (USD Million)
- Fig. 43 U.S. epilepsy market, 2021 - 2033 (USD Million)
- Fig. 44 U.S. other cancer-related treatments market, 2021 - 2033 (USD Million)
- Fig. 45 U.S. severe protein allergy market, 2021 - 2033 (USD Million)
- Fig. 46 U.S. others market, 2021 - 2033 (USD Million)
- Fig. 47 U.S. Medical foods market Sales channel outlook and key takeaways
- Fig. 48 U.S. Medical foods market Sales channel movement analysis
- Fig. 49 U.S. DTC sales channel market, 2021 - 2033 (USD Million)
- Fig. 50 U.S. online sales market, 2021 - 2033 (USD Million)
- Fig. 51 U.S. retail sales market, 2021 - 2033 (USD Million)
- Fig. 52 U.S. hospitals channel market, 2021 - 2033 (USD Million)
- Fig. 53 U.S. Others (Long-term Care Facilities, etc.) market, 2021 - 2033 (USD Million)
- Fig. 54 Market participant categorization
- Fig. 55 Strategy framework
- Fig. 56 Company market position analysis, 2025
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.